news
FDA approves Glatopa a generic option for relapsing forms of multiple sclerosis
Sandoz has announced that the FDA has approved and launch of Glatopa as a fully-substitutable, AP-rated generic version of Copaxone for relapsing forms of MS...
List view / Grid view
Generics
news
Report identifies two-tier pharmaceuticals market
A report released has identified a two-tier manufacturing market and forecast increased acquisitions by Indian companies...
news
HerpV and GEN-003 will drive genital herpes treatment market growth to 2023
21 July 2015 | By Victoria White
The global market value for genital herpes therapeutics will increase from approximately $490 million in 2013 to just under $668 million by 2023, largely driven by the introduction of therapeutic vaccines, HerpV and GEN-003, towards the end of the forecast period, says research and consulting firm GlobalData.
